Transfer of the herpes simplex virus type I-thymidine kinase gene, followed by the administration of ganciclovir (HSV 1 -tk/GCV) into ovarian cancer-derived cell line either in vitro or transplanted into nude mice has been shown to provide a potential strategy for the gene therapy of ovarian cancer. We investigated the antitumor effects of HSV 1 -tk/GCV strategy with a chemically induced rat ovarian cancer model and a tumor-selective gene delivery by a novel nonviral gene delivery system (GE7) through the ovarian artery and tail vein. We demonstrated the expression of a reporter gene, b-gal gene, as well as HSV 1 -tk gene in tumors and other organs, evaluated the overall antitumor effects after the GCV treatment and analyzed the tumor cell cycle phase distribution. Via the ovarian artery route, the expressions of b-gal and HSV 1 -tk in tumors were significantly stronger than those expressed in such organs as the hearts, livers, spleens, lungs and kidneys. However, no b-gal and HSV 1 -tk were detected in the tumor tissues when administrated via the tail vein, and little was found in other organs. The cell cycle analysis showed that the total S-phase of tumor cells in the test intra-arterial treatment group was considerably higher than that of the controls. The weight of the tumor tissues in the group treated by the intra-arterial route (4.0672.12 g) was much less than the group treated intravenously (18.2578.34 g) (Po.01). These findings indicated that the administration of GE7/HSV 1 -tk complex via the ovarian artery route could be a promising avenue of future human ovarian cancer treatment.
D espite recent advances in the chemotherapy of ovarian cancer, [1] [2] [3] [4] [5] only 73% of stage III and IV patients respond to therapy and overall prognosis remains poor. Therefore, alternative approaches are pursued to improve and prolong therapeutic effects in patients with the condition. Some new strategies involving gene therapies are being examined in animal models 6 and in clinical trials. 7 The HSV 1 -tk/GCV system has been a focus in gene therapies for most malignancies including ovarian cancer. 8 Several clinical trials have examined such a system in patients with ovarian cancers demonstrating promising antitumor effects. [9] [10] [11] However, these studies also indicate high incidence of side effects such as fever, abdominal pain and injuries of normal organs, which may result from the transfer of therapeutic genes to normal cells either through a nontarget viral vector or the vector itself.
Therefore, many researchers are trying to improve gene therapy after these early clinical trials. Major challenges of the translation of gene therapy technology of malignancies, including ovarian cancer, to humans are the development of better vectors 12 and the identification of tumor-specific promoters and tumor-specific targets. 13 Based on the fact that aberrant overexpression of epithelial growth factor receptor (EGFR) was observed in a variety of human cancer cells, 14 as well as ovarian cancer cells, 15 a novel nonviral gene delivery system, designated as GE7 system, which contains a 16-aminoacid ligand for identifying EGFR, was constructed for a tumor-targeted gene therapy. 16 In previous reports, the gene transfer of p21 WAFÀ1 and GM-CSF combined using this system could exhibit an enhanced antitumor effect in tumor-bearing mice both after peritumoral and intravenous injections. As previously reported, 17 EGFR was overexpressed in most ovarian cancer cells so the target GE7 delivery system can be used as a vector in the research of the gene therapy for ovarian cancer. EGFR was, however, normally expressed in all other organs. 18 If the system was performed intravenously or via intraperitoneum, the therapeutic gene would target those normal tissues, thus inducing side effects. These observations stressed the need, when designing the routes of administration, for the use of a proper animal model. Tumors developed in immunodeficient mice are extremely valuable for investigating the parameters of the therapeutic effects of HSV 1 -tk expression, but they clearly cannot enable us to address the specific problems encountered in women ovarian cancers.
To address this issue, we and others have been investigating rat ovarian cancer induced by 7, 12-dimethylbenz[a]anthracene (DMBA). In this classical model of ovarian carcinogenesis, ovarian cancer develops in immunocompetent animals. We investigated this model in detail, and found that the ovarian arteries is always enlarged and easy to expose as compared those in normal rats, thus pointing to the feasibility of selective intraartery injections.
The present study revealed the high efficiency and specificity of antitumoral effects of HSV 1 -tk/GCV gene therapy system in a DMBA-induced rat ovarian cancer models mediated by GE7 delivery system by intra-artery routes. Our results lead us to propose different modalities in gene therapy for the early treatment of ovarian cancer.
Materials and methods

Tumor induction and evaluation
Female Wistar rats (8 weeks old, 140-160 g) were purchased from the Experimental Animal Center of Fudan University. Throughout the experiment, all of the rats were housed under a controlled environment with 12 hour light/dark cycles and a temperature of 22721C, and provided a commercial diet with tap water and libitum. The rats were acclimated for 1 week before being treated. DMBA (Sigma Chemical Co, St Louis, MO) was heated to 1241C, which was the fusion point of the carcinogen. A central portion of 3-0 silk suture was immersed in the melted DMBA; sutures contained approximately 0.4 mg of the carcinogen on average. Under anesthesia with Ketamine Hydrochloride Injection (Shanghai NO.1 Biochemical & Pharmaceutical Co, Shanghai, China) at 50 mg/kg i.p., both ovaries were exposed surgically and the membranous bursa was removed to avoid a misguided insertion to the tube. A DMBA-coated suture was then inserted into both ovaries and knotted. Tumor number, size and volume were determined weekly after the first operation.
Preparation of GE7/DNA complexes GE7(a 16-peptide specific to EGFR), and HA20 (a homologue of N-terminus of haem agglutinin of influenza viral envelope protein), were synthesized by the National Laboratory for Oncogenes and Related Genes, Shanghai Cancer Institute. GE7 and HA20 were conjugated with polylysine (PL), (GE7-PL and HA20-PL), pCMV-b-gal or pCMV-HSV 1 -tk plasmid DNA (constructed by National Laboratory for Oncogenes and Related Genes, Shanghai Cancer Institute), GE7-PL and HA20-PL conjugates were mixed into 10 ml of deionized water in different ratios. The mixture was incubated at 251C for 30 minutes. A mixture containing 0.2 mg plasmid DNA was analyzed on 1% agarose gel electrophoresis to exam the retardation of DNA migration, in order to determine an optimal ratio. According to the optimal ratio of DNA to conjugates based on the experiment mentioned above, the plasmid DNA was mixed to the conjugates of GE7-PL and HA20-PL for reaction at 251C for 30 minutes. Then the complexes containing plasmid 8 mg/ml could be used for gene transfection. The GE7-PL/DNA/HA20-PL polyplexes used in the following transfection were abbreviated as GE7/b-gal and GE7/ HSV 1 -tk.
In vivo gene therapy
All the animal experiments were conducted in accordance with the National Institutes of Health ''Guide for the Care and Use of Laboratory Animals.'' The study protocol was approved by Shanghai Medical Experimental Animal Care Committee.
Efficacy of exogenous gene transduction mediated by GE7/b-gal complex via ovarian artery and tail vein
In all, 15 rats with DMBA-induced ovarian tumors were randomly divided into three even groups. In the first group, each rat was anesthetized with Ketamine Hydrochloride Injection and ovarian tumor was surgically exposed. With the assistance of an operation microscope, the ovarian artery was exposed, into which 1 ml volume of GE7/b-gal complex was then injected (containing b-gal plasmid DNA 8 mg). At the end of the operation, the ovarian artery was knotted for the purpose of hemostasia. In the second group, the same procedures were performed, but with a half volume of the complex. In the last group, 1 ml volume of the complex was injected into the tail veins under no anesthesia. All the rats were killed 72 hours after injection and the tumors, hearts, livers, spleens, lungs, and kidneys were dissected, and fixed in PBS solution containing 2% formaldehyde and 0.2% glutaraldehyde for 1 hour at 41C. Having been washed with PBS thrice, they were stained with X-gal solution (1 mg/ml 5-bromo-4-chloro-3-indolyl-b-D-galactopy-ranoside, 5 mM K 4 [Fe(CN) 6 ] and 2 mM MgCl 2 ) for 48 hours at 371C. For histological examination, stained tissues of the tumors and other organs were frozensectioned and counterstained with neutral red.
In vivo gene transduction of GE7/HSV 1 -tk complex via an ovarian artery and tail vein Nine rats with DMBA-induced ovarian tumors were randomly divided into three groups with three rats even in Efficiency and specificity of ovarian cancer gene therapy W Jiang et al each group. Each rat of the first group was injected with 1 ml volume of GE7/HSV 1 -tk complex(containing HSV 1 -tk plasmid DNA 8 mg) via an ovarian artery as previously described; each of the second group, with only saline buffer through the same procedure as was performed for the first group; each of the last group, with 1 ml volume of GE7/HSV 1 -tk complex via the tail vein. All the rats were killed 72 hours after injection and the tumors, hearts, livers, spleens, lungs, and kidneys were dissected and stored at À801C after being snap-frozen in liquid nitrogen for the future use of RT-PCR and Western blot analysis of HSV 1 -tk gene and protein expression.
RNA isolation and RT-PCR analysis
RT-PCR analysis was carried out to examine the mRNA expression of exogenous HSV 1 -tk in both tumors and other organs. Total RNA was isolated from about 5 mm 3 fresh rat tissues using Trizol reagent (Life Technologies, Inc.) according to the manufacturer's instructions. One microgram of total RNA was converted to cDNA using an avian myeloblastosis virus reverse transcription system (Promega, Madison, WI), and 2.5 ml out of each RT reaction mixture was applied to 25 ml of PCR mixture containing 2.5 U AmpliTaq DNA polymerase (Promega, Madison, WI), 1.5 mmol/l MgCl2, 1 Â Taq buffer and 0.2 mmol/l 4 deoxynucleotide triphosphates (dNTPs). The specific primers of GAPDH and HSV 1 -tk used in the experiment were as follows:
In all, 30 cycles of PCR were carried out with the program of 45 seconds at 941C, 40 seconds at 581C and 1 minute at 721C, followed by a final extension period of 7 minutes at 721C. Part of the PCR product was electrophoresed on 1.5% agarose gel and presented on an Alpha Image 950 documentation system (Alpha Innotech, San Leandro, CA). Densitometry of the images was performed using NIH Image version 1.62.
Western blot analysis
Western blot analysis was conducted to examine the protein expressions of exogenous HSV 1 -tk in both the tumors and organs, the tissues of which were snap-frozen in liquid nitrogen and grinded into debris, and were washed twice in ice-cold PBS and scarped into 1 ml of icecold NP40 lysis buffer (10 mM Tris-HCl (pH 8.0), 150 mM NaCl, 1% (v/v) NP40, 1 mM EDTA, 50 mM NaF, 5 mM Na PPI, 1 mM phenylmethylsulfonyl fluoride, 1 mg/ml leupeptin and 1 mg/ml pepstatin A). Insoluble debris was removed by centrifugation at 1000 g for 15 minutes. Total proteins (50 mg) were analyzed by 10% SDS-PAGE. Western blot with mouse monoclonal antibodies to HSV 1 -tk protein (Abcam Ltd, Cambridge, UK) diluted 1:500, was performed according to standard protocols. 19 Blot quantitation was performed with a Molecular Dynamics Laser Densitometer (Model PSD) and the Image Quant Version 1 software, and the normalization of protein loading was carried out with b-actin.
In vivo tumor-inhibitory experiments
In all, 21 rats with DMBA-induced ovarian tumors were randomly divided into three even groups, which first underwent respectively exactly the same procedure performed previously in our study. After 72 hours, all the rats received a dose of 50 mg/kg/day GCV (F Hoffmann-La Roche Ltd, SW) diluted in saline buffer by i.p. administration for 10 days, and were killed 3 days after the treatment and the tumors and organs were dissected. Afterwards, the tumor weights were measured to assess the antitumor response, and the tumor inhibitory rate was calculated by the following formula: (The mean weight of tumors in the saline buffer group-The mean weight of tumors in the artery or tail vein injection group) / The mean weight of tumors in the saline buffer group Â 100%.
Analysis of tumor cell cycle phase distribution
Flow cytometry analysis of DNA content was performed to assess the cell cycle phase distribution as described previously. 20 Fresh tumor tissues of the three groups were obtained and were made single-cell fluids and stained for DNA content using propidium iodide fluorescence. The computer program Multicycle from Phenix Flow System (San Diego, CA) was used to generate histograms so as to determine the cell cycle phase distribution.
Statistical analysis
Analysis of variance and Student's t-test were applied to the determination of the statistical significance of differences between the test group and two groups of controls, with the results represented as mean7SEM.
Results
Tumor development
In our study the incidence rate of neoplastic lesions was 67.6% 45 weeks after the first application of DMBA, which was similar with what has been previously reported. 21 Histological studies showed that they presented all features of cellular alterations characteristic of a process of ovarian carcinogenesis such as adenocarcinomas, sarcomas, low or undifferentiated carcinomas, as described by Kim et al 22 (data not shown).
Construction of GE7-DNA complex
Polypeptide and pCMV-HSV 1 -tk or pCMV-b-gal plasmids DNA were mixed in different ratios. According to the results of 1% agarose electrophoresis, pCMV-HSV 1 -tk DNA was completely trapped at the slot with no DNA migration when the ratio was 1:1 (Fig 1) . This was the optimal ratio of polypeptide to pCMV-HSV 1 -tk or pCMV-b-gal plasmid DNA.
Efficiency and specificity of ovarian cancer gene therapy W Jiang et al Transduction efficiency and specificity of GE7/b-gal complex
To observe the efficiency and targetability of GE7 gene delivery system when administrated via an intra-artery route, the expression of a reporter gene, b-gal, was observed in ovarian tumors and organ tissues following intra-artery (in different doses) or tail vein injections of GE7/b-gal complex. It was revealed in the first group of rats that the tumor tissues possessed a high level of and a welldistributed expression when injected with 8 mg GE7/b-gal DNA, and presented a much weaker expression in such organs as the hearts, livers, spleens, lungs and kidneys. In the second group almost no reporter gene expression was detected in such organs when the dose of DNA was reduced to 4 mg via an intra-artery route. In the third group only the expression was found to be in the lungs (Fig 2) . All of these results indicated that intra-artey administration of the GE7 delivery system could target exogenous genes on ovarian cancer cells for high efficiency and specificity.
In vivo gene transduction by GE7/HSV 1 -tk complex via ovarian artery and tail veins
RT-PCR was carried out to investigate the expression of HSV 1 -tk mRNA. In the first group in question, HSV 1 -tk mRNA expressed in tumor tissues was much stronger than that in organ tissues. Only a few HSV 1 -tk gene expressions were found to be in the lungs, kidneys, livers and almost none was expressed in the hearts and spleens. In the second group none of such expression was detected. In the third group, however, the expression, not expressed in the tumor tissues, was observed in the lungs, spleens, livers, kidneys and hearts, at a degree much lower than that detected in the tumor tissues of the first group (Fig 3) . From the analysis using Western blot, we found the same pattern of HSV 1 -tk protein expressions as that of HSV 1 -tk mRNA by RT-PCR (Fig 4) .
In vivo tumor inhibitory experiments
In the first group all the rats survived the experiment; one rat died of tumor progression in the second group and two met the same fate in the third group. In the first group, the tumors showed necrosis and bleeding in the surface after administration of GE7/HSV 1 -tk complex containing HSV 1 -tk DNA 8 mg followed by 10 days of GCV injection i.p., while these conditions were not observed in the second and third group. It was found that the tumor weight in the first group (4.0672.12 g) was much lighter than that in the second (14.6676.26 g) (Po.01) and third group (18.2578.34 g) (Po.01), with the tumor inhibitory rate 72.3% (Fig 5 and Table 1 ). Nevertheless, the tumor weight in the third group was even higher than that in the second, suggesting that the dosage administered via a tail vein in our study had no antitumor effects.
Analysis of cell cycle phase distribution
The results from flow cytometry analysis showed that the percent of S-phase of tumor cells in the first group was 52.38712.25%, higher than that of the second (31.43710.35%, Po.05) and the third group (27.4379.22%, Po.05). The apoptosis rate was 38.37711.23, 14.3276.43 and 11.8675.28%, respectively (Po.05) (Fig 6 and Table 2 ). Efficiency and specificity of ovarian cancer gene therapy W Jiang et al
Discussion
The present study provided compelling evidence that HSV 1 -tk/GCV-GE7 gene therapy system had strong antitumor effects in a rat model of chemically induced ovarian cancer via an intra-artery route. Vital requirements for successful gene therapy include efficient and specific delivery of transgenes onto target Weight of Tumor (g) Figure 5 The ovarian tumors and their weights of three groups after treatments. In all, 21 rats ovarian tumor were randomly divided into three even groups. The rats in three groups were injected with GE7/ HSV 1 -tk complex or saline buffer via ovarian artery and GE7/HSV 1 -tk complex via tail vein. At 72 hours after operation, all rats received a dose of 50 mg/kg/day GCV by i.p. administration for 10 days. All rats were killed 3 days after the final dose of GCV and the tumors were dissected. Lane 1: The ovarian tumors with GE7/HSV 1 -tk injection through tail vein. Lane 2: The ovarian tumors with saline buffer injection through ovarian artery. Lane 3: The ovarian tumors with GE7/HSV 1 -tk injection via an ovarian artery.
Efficiency and specificity of ovarian cancer gene therapy W Jiang et al cells; stable expression of transgenes and minimal side effects for the recipients. 23 Thus, the vector is one of the most important factors of gene therapy research. Compared with the viral vector, a nonviral delivery system has advantages, such as safety and relatively low immunogenicity. 24 In 1998, Tian et al, 25 developed a composite polypeptide comprising synthetic GE7 (a 16-peptide specific to EGFR) and HA20 (a homologue of Nterminus of haem agglutinin of influenza viral envelope protein), which could be covalently conjugated to polylysine. Exogenous genes packaged with GE7-polylysine/HA20-polylisine could target tumors cells with overexpressed EGFR both in vitro and in vivo. However, the expression of EGFR is not limited to tumor cells. For instance, Chun-Hong Ma et al, 26 reported that a reporter gene could be also expressed in the cells of the stomachs, livers, and spleens after being transfected with GE7 4-element complex in vivo.
So far HSV 1 -tk/GCV gene therapy for ovarian cancer has being experimented with mostly in tumors transplanted into nude mice or syngeneic rats and made a great progress. [1] [2] [3] [4] It is, however, important to emphasize that such an approach does not reflect the in vivo situation. DMBA-induced ovarian carcinogenesis provides a wellcontrolled experimental model of ovarian cancer. 27, 28 The development of ovarian cancer in such a model could resemble that developed in women, which was therefore can be introduced into our study on an interventional gene therapy for ovarian cancer.
In the present study, we demonstrated a specific and successful gene delivery into DMBA-induced ovarian cancerous cells through an intra-artey injection of GE7/bgal complex. We also examined the in vivo HSV 1 -tk expression following a gene transfer with the GE7 delivery system administrated through an ovarian artery in the model established. The results indicated that strong b-gal expressions could be detected in tumor tissues, and RT-PCR and Western blot analyses demonstrated high expression levels of HSV 1 -tk mRNA and protein in the ovarian tumors when they were administrated through the ovarian artery, and extremely low levels in the organs. These results were found to be similar to those reported by Laurema et al. 29 Through artery administration, a high concentration could be obtained in the target organs of artery with a relative low dose of drug, 30 and we got herein the same results. GCV was administered i.p.
following the transfection of HSV 1 -tk gene with an ovarian artery injection, which produced significant antitumor effects. However, it was of no effect when administrated via a tail vein, the possible explanation of which could be that GE7/HSV 1 -tk complex might be Efficiency and specificity of ovarian cancer gene therapy W Jiang et al decomposed during blood circulation or observed by organ tissues. Interestingly enough, the tumor inhibitory rate was À19.7% in the tail vein group, suggesting that the tumors there grew even bigger than those of the controls. The mechanism could be explained in terms of the fact that the ovarian arteries were knotted in the test and control group, but not in the tail vein group, and the block of blood supply to the tumor could inhibit its progress.
Application of drug sensitization with the HSV 1 -tk/ GCV system in solid tumors was pioneered by Mootlen and others and has been used in clinical trails of brain cancer, leptomeningeal carcinoma, ovarian tumor, breast cancer and hepatocellular carcinoma. [31] [32] [33] The mechanism involved in tumor regression could be that HSV 1 -tk gene transfer to tumor cells results in the phosphorylation of GCV to toxic nucleotide precursors, which in turn disrupt DNA synthesis in cells expressing the transgene, as well as uninfected neighboring tumor cells (so-called ''bystander effect''). 34 The stimulation of an immune response against tumor cells was hypothesized to be a important factor in this therapeutic paradigm. 35 Since DNA synthesis was blocked during the treatment of HSV 1 -tk/GCV system, the S-phase (synthesis phase) in the cell cycle was hypothesized to increase, and this was verified by flow cytometry analysis in our study. Cell death caused by nucleoside analogs such as GCV is mediated by apoptosis, 36 which was also confirmed in our study.
In conclusion, our results indicated that HSV 1 -tk/GCV gene therapy system could present strong antitumor effects through the mediation of GE7 delivery system in a rat model of chemically induced ovarian cancer via an intra-artery route.
